ArticleMedicine2025
Unraveling the Crimson puzzle: Two case reports/case series of hemorrhagic cystitis after combination chemotherapy with docetaxel, carboplatin, trastuzumab and pertuzumab in breast cancer.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationaleHemorrhagic cystitis can be a serious side effect of some chemotherapy drugs like cyclophosphamide and ifosfamide. Docetaxel is a taxane that is used to treat several malignancies including breast and prostate cancer. Hemorrhagic cystitis has not been described as a complication of combination chemotherapy with docetaxel, particularly docetaxel with carboplatin, trastuzumab and pertuzumab (TCHP) in breast cancer patients. PATIENT CONCERNS: Both patients had a history of locally advanced human epidermal growth factor receptor 2 positive breast cancer and complaint of hematuria after their first treatment with TCHP. DIAGNOSES: They were diagnosed with hemorrhagic cystitis.
interventionsDocetaxel was discontinued and changed to paclitaxel. OUTCOMES: Both patients completed neoadjuvant chemotherapy and did not have further episodes of hemorrhagic cystitis. LESSONS: Hemorrhagic cystitis is a rare complication of combination chemotherapy with docetaxel (TCHP). Clinicians should be vigilant for signs and symptoms of hemorrhagic cystitis in patients receiving docetaxel and alternative treatment option should be considered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.